SCH 58261 [160098-96-4]
Référence T6979-5mg
Conditionnement : 5mg
Marque : TargetMol
Select Batch
Purity:99.91%
Color:White
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SCH 58261 is a potent and selective A2a adenosine receptor antagonist.The Ki =2.3 nM for rat A2a and 2 nM is for bovine A2a. |
| Targets & IC50 | A2a (bovine):2.0 nM(Ki), A2A (rat):2.3 nM(Ki) |
| In vitro | SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1] |
| In vivo | In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3] |
| Synonyms | SCH58261 |
| Molecular Weight | 345.36 |
| Formula | C18H15N7O |
| Cas No. | 160098-96-4 |
| Smiles | Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1 |
| Relative Density. | 1.54g/cm3 |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 35.71 mg/mL (103.4 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: < 3.57 mg/mL (10.34 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. ![]() 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.57 mg/mL (10.34 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||




